CLGN icon

CollPlant Biotechnologies

1.42 USD
-0.26
15.48%
At close Jun 13, 4:00 PM EDT
After hours
1.49
+0.07
4.93%
1 day
-15.48%
5 days
-28.28%
1 month
-8.39%
3 months
-55.06%
6 months
-61.52%
Year to date
-62.73%
1 year
-71.60%
5 years
-85.80%
10 years
-84.13%
 

About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Employees: 57

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

14% more funds holding

Funds holding: 14 [Q4 2024] → 16 (+2) [Q1 2025]

0.16% more ownership

Funds ownership: 11.12% [Q4 2024] → 11.28% (+0.16%) [Q1 2025]

27% less capital invested

Capital invested by funds: $4.59M [Q4 2024] → $3.33M (-$1.25M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$12
745%
upside
Avg. target
$12
745%
upside
High target
$12
745%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
D. Boral Capital
Jason Kolbert
745%upside
$12
Buy
Maintained
30 May 2025

Financial journalist opinion

Based on 4 articles about CLGN published over the past 30 days

Neutral
PRNewsWire
6 days ago
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
CollPlant's proprietary rhCollagen to be used in clinical and commercial applications REHOVOT, Israel , June 9, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen)  for tissue regeneration and medical aesthetics, today announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine, immunology, and related life sciences. The amended agreement broadens the use of CollPlant's rhCollagen, extending beyond research applications to include clinical development and commercial-scale manufacturing.
COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES
Neutral
PRNewsWire
1 week ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
- Further protection granted in key territory applying to the significant and growing aesthetic and reconstructive markets - REHOVOT, Israel , June 4, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant's injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. This newly allowed patent application pertains to CollPlant's injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS
Neutral
PRNewsWire
2 weeks ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
REHOVOT, Israel , May 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,200,002 of the Company's ordinary shares at a purchase price of $3.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered to purchase up to 1,200,002 of the Company's ordinary shares at an exercise price of $3.00 per share.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Neutral
PRNewsWire
2 weeks ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
- In Q1 following a development achievement, CollPlant received a $2 million payment from AbbVie – - Advancement of regenerative breast implant program continues; encouraging findings continue to be observed -  REHOVOT, Israel , May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core programs, we've remained disciplined in optimizing costs and prioritizing initiatives that are designed to support a well-capitalized path forward in the best interest of our shareholders.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
Neutral
PRNewsWire
1 month ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
REHOVOT, Israel , May 14, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter on Wednesday, May 28, 2025, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS
Neutral
PRNewsWire
2 months ago
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
CollPlant's novel rhCollagen BioInks are an available solution aligned with FDA's plan announced last week to phase out the animal testing requirement for the development of monoclonal antibody therapies and other drug candidates REHOVOT, Israel , April 15, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, commented today, following the United States Food and Drug Administration (FDA)'s groundbreaking step announced last week to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drug candidates with more effective, human-relevant methods. Importantly, CollPlant's Collink.3D ®  portfolio of rhCollagen-based BioInk products can be utilized for the biofabrication of tissue-on-a-chip or organ-on-a-chip systems, which serve as alternatives to animal testing.
CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies
Neutral
Seeking Alpha
2 months ago
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C.
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
2 months ago
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
Neutral
PRNewsWire
2 months ago
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Conference call to be held on Wednesday, March 26, 2025 at 10:00 a.m. U.S. EST REHOVOT, Israel , March 19, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the fourth quarter and full year of 2024 on Wednesday, March 26, 2025, before the opening of the U.S. financial markets.
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
Neutral
PRNewsWire
3 months ago
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
REHOVOT, Israel , Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, and hand tendons.
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
Charts implemented using Lightweight Charts™